TABLE 2

Second Study: Patient Data

TSH (mU/L)*Tg (ng/mL)Neck 131I (24-h %)TreatmentRx/Dx
Patient no.SexAge (y)OutsetEndRatioTg (ng/mL)mCiPattern2 d1 d0.25 d0 d
1F3986911.0611.38155A0.120.411.221.77
2M352151790.83Antibody1.9146A0.130.350.720.94
3F401621370.85Antibody1.4145B0.750.870.890.87
4M3469670.970.81.429C1.771.371.301.32
5F3498NDAntibody1.6150A0.351.796.9011.3
6F30118870.74Antibody0.231A0.240.712.002.34
7F3577690.911.616.529A0.540.590.640.66
8M212651430.536319146A0.330.580.850.97§
[0.550.901.431.67]
9F371181211.031.42.330C1.431.681.851.91
10F341541350.885.61.830B0.820.680.640.63
Mean0.870.651.011.632.26
SD0.160.560.651.953.92
  • * TSH measured at outset of Dx dose and at end of Rx measurements.

  • End/outset.

  • Group for analysis of data (see text).

  • § Values for thyroid tissue.

  • Values for lymph nodes; these are excluded from means and SD.

  • Tg = thyroglobulin; ND = not done.